Bibliographies thématiques / Antithrombotic strategies

Littérature scientifique sur le sujet « Antithrombotic strategies »

Auteur : Grafiati
Publié le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Antithrombotic strategies ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Antithrombotic strategies"

1

Guedeney, Paul, et Jean-Philippe Collet. « Antithrombotic strategies following TAVR ». Sang thrombose vaisseaux 33, no 1 (février 2021) : 19–24. http://dx.doi.org/10.1684/stv.2021.1155.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Hasan, Md Nazmul, Md Abu Siddique, Sajal Krishna Banerjee, Syed Ali Ahsan, AKM Fazlur Rahman, Choudhury Meshkat Ahmed, Mohammad Faisal Ibn Kabir et Md Harisul Hoque. « Antithrombotic Strategies in Perioperative Period ». University Heart Journal 9, no 1 (14 juillet 2014) : 47–51. http://dx.doi.org/10.3329/uhj.v9i1.19511.

Texte intégral
Résumé :
Antithrombotic therapy (Warfarin, Aspirin,Clopidogrel etc.) are routinely used in prevention and treatment of various cardiovascular diseases. In patients who are having a surgical or other invasive procedure, interruption of antithrombotic therapy is typically required to minimize the risk for perioperative bleeding. It involves balancing the risk of periprocedural bleeding with continued treatment against the thrombotic risk with suspension of treatment and use of bridging anticoagulation therapy. The need for bridging is driven by patients’ estimated risk for thromboembolism and the bleeding risk of invasive procedure. Treatment with subcutaneous low-molecular- weight heparin or intravenous unfractionated heparin at a therapeutic dose before and after the procedure recommended as bridging anticoagulation therapy. DOI: http://dx.doi.org/10.3329/uhj.v9i1.19511 University Heart Journal Vol. 9, No. 1, January 2013; 47-51
Styles APA, Harvard, Vancouver, ISO, etc.
3

Gremmel, Thomas, et Kurt Huber. « Antithrombotic treatment strategies after PCI ». Lancet 395, no 10227 (mars 2020) : 865. http://dx.doi.org/10.1016/s0140-6736(20)30028-3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

De Caterina, Raffaele, et Ugo Limbruno. « Antithrombotic treatment strategies after PCI ». Lancet 395, no 10227 (mars 2020) : 865. http://dx.doi.org/10.1016/s0140-6736(20)30029-5.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Jeong, Young-Hoon, Yong-Lee Kim, Udaya Tantry et Paul A. Gurbel. « Antithrombotic treatment strategies after PCI ». Lancet 395, no 10227 (mars 2020) : 866–67. http://dx.doi.org/10.1016/s0140-6736(20)30030-1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Romiti, Giulio Francesco, Stefania Basili et Marco Proietti. « Antithrombotic treatment strategies after PCI ». Lancet 395, no 10227 (mars 2020) : 866. http://dx.doi.org/10.1016/s0140-6736(20)30031-3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Auer, Johann, Robert Berent et Franz Gurtner. « Antithrombotic treatment strategies after PCI ». Lancet 395, no 10227 (mars 2020) : 865–66. http://dx.doi.org/10.1016/s0140-6736(20)30032-5.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Channon, Keith M., et Brian H. Annex. « Antithrombotic strategies in gene therapy ». Current Cardiology Reports 2, no 1 (janvier 2000) : 34–38. http://dx.doi.org/10.1007/s11886-000-0023-4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Gurbel, Paul A., Palak Shah, Shashank Desai et Udaya S. Tantry. « Antithrombotic Strategies and Device Thrombosis ». Cardiology Clinics 36, no 4 (novembre 2018) : 541–50. http://dx.doi.org/10.1016/j.ccl.2018.06.008.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Shishehbor, Mehdi H., et Barry T. Katzen. « Antithrombotic Strategies in Endovascular Interventions ». Interventional Cardiology Clinics 2, no 4 (octobre 2013) : 627–33. http://dx.doi.org/10.1016/j.iccl.2013.06.005.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Antithrombotic strategies"

1

Bellandi, Benedetta. « Pharmacodynamic of antithrombotic therapies in high cardiovascular risk patients ». Doctoral thesis, 2018. http://hdl.handle.net/2158/1129305.

Texte intégral
Résumé :
This thesis addresses different aspects of antithrombotic strategies in patients with acute coronary syndrome, mainly in ST elevation acute myocardial infarction (STEMI) patients treated with percutaneous coronary intervention (PCI), regarding their efficacy and safety during the acute phase as well as their appropriateness and impact on long-term outcomes.
Styles APA, Harvard, Vancouver, ISO, etc.

Livres sur le sujet "Antithrombotic strategies"

1

Askari, Arman. Management strategies in antithrombotic therapy. Chichester : John Wiley and Sons, 2007.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Askari, Arman, Michael Lincoff et Adrian Messerli. Management Strategies in Antithrombotic Therapy. Wiley & Sons, Incorporated, John, 2008.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Askari, Arman, Michael Lincoff et Adrian Messerli. Management Strategies in Antithrombotic Therapy. Wiley & Sons, Limited, John, 2007.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Management Strategies in Antithrombotic Therapy. Wiley-Interscience, 2008.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

McDonald, Vickie, et Marie Scully. Anticoagulants and antithrombotics in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0051.

Texte intégral
Résumé :
Coagulation is best thought of using the cell-based model of coagulation. Patients commenced on heparin therapy should have their platelet count monitored early because of the risk of heparin-induced thrombocytopenia, which can occur on any type or dose of heparin. Emergency reversal of warfarin should be with prothrombin complex concentrate (containing factors II, VII, IX, and X) and not fresh frozen plasma. New oral anticoagulants have the advantage of predictable pharmacokinetics and do not require routine monitoring, but optimal reversal strategies for these agents are not clear. Thrombolytic agents lead to variable degrees of systemic lysis, which may cause haemorrhage, including intracerebral haemorrhage
Styles APA, Harvard, Vancouver, ISO, etc.
6

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0070.

Texte intégral
Résumé :
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drugs (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199687039.003.0070_update_001.

Texte intégral
Résumé :
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drugs (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199687039.003.0070_update_002.

Texte intégral
Résumé :
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drug usage (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), such thrombotic microangiopathies as thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Antithrombotic strategies"

1

Bitar, Jamil, Salim Dabaghi, Selim Sekili et Neil S. Kleiman. « Novel Antithrombotic Strategies ». Dans Unstable Coronary Artery Syndromes Pathophysiology, Diagnosis and Treatment, 241–75. Boston, MA : Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5715-9_7.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Leblond, L., et P. D. Winocour. « The Coagulation Pathway and Antithrombotic Strategies ». Dans Antithrombotics, 1–39. Berlin, Heidelberg : Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59942-2_1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Shishehbor, Mehdi H. « Antithrombotic Strategies in Endovascular Interventions ». Dans Interventional Cardiology, 754–58. Chichester, UK : John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118983652.ch82.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Schoos, Mikkel Malby, Davide Capodanno et George D. Dangas. « Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions ». Dans Interventional Cardiology, 507–16. Chichester, UK : John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118983652.ch53.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Rao, Sunil V., et E. Magnus Ohman. « Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention ». Dans Therapeutic Advances in Thrombosis, 236–45. Oxford, UK : Blackwell Publishing Ltd., 2012. http://dx.doi.org/10.1002/9781118410875.ch16.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Deckmyn, H., P. Gresele, J. Arnout et J. Vermylen. « Manipulation of Pro- and Antiaggregating Prostaglandins : New Antithrombotic Strategies ». Dans Drugs Affecting Leukotrienes and Other Eicosanoid Pathways, 141–47. Boston, MA : Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-7841-9_12.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Margaglione, M., E. Grandone, F. P. Mancini et G. Di Minno. « Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies ». Dans Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques, 169–81. Basel : Birkhäuser Basel, 1996. http://dx.doi.org/10.1007/978-3-0348-8996-4_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Wali, Eisha, et Sandeep Nathan. « Newest Antithrombotic Agents : Uses, Challenges, and Reversal Strategies for Surgical Procedures ». Dans Difficult Decisions in Surgery : An Evidence-Based Approach, 481–97. Cham : Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-04146-5_33.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Mejevoi, Nicolai, Catalin Boiangiu et Marc Cohen. « Antiplatelet therapy versus other antithrombotic strategies ». Dans Platelets in Hematologic and Cardiovascular Disorders, 367–85. Cambridge University Press, 2001. http://dx.doi.org/10.1017/cbo9780511545276.023.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Kristensen, Steen D., Kurt Huber et Michael Maeng. « Risk reduction strategies : perioperative management in patients on antithrombotic therapy ». Dans ESC CardioMed, sous la direction de Steen Kristensen, 2657–59. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0638.

Texte intégral
Résumé :
The choice of disruption or continuation of antithrombotic drugs prior to non-cardiac surgery is a challenging issue for surgeons and cardiologists. The type of surgery, cardiac diagnosis, and indication for antithrombotic therapy should be evaluated and discussed. This chapter provides some guidance for clinicians on how to balance bleeding and perioperative thrombotic complications.
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Antithrombotic strategies » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie